Recent Finacing
Recent Raise
BioRelix develops antibiotics using a riboswitch-based drug discovery platform that targets regulatory mRNA controlling essential bacterial genes, advancing programs including a hospital-acquired infection antibiotic and a Merck collaboration.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors